476 related articles for article (PubMed ID: 31027362)
1. Interplay Between SOX9, Wnt/β-Catenin and Androgen Receptor Signaling in Castration-Resistant Prostate Cancer.
Khurana N; Sikka SC
Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027362
[TBL] [Abstract][Full Text] [Related]
2. Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancer.
Xie Y; Lu W; Liu S; Yang Q; Carver BS; Li E; Wang Y; Fazli L; Gleave M; Chen Z
Mol Endocrinol; 2014 Oct; 28(10):1629-39. PubMed ID: 25099011
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol inhibits hypoxia-inducible factor-1α-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer.
Mitani T; Harada N; Tanimori S; Nakano Y; Inui H; Yamaji R
J Nutr Sci Vitaminol (Tokyo); 2014; 60(4):276-82. PubMed ID: 25297617
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
5. Activation of β-Catenin Cooperates with Loss of Pten to Drive AR-Independent Castration-Resistant Prostate Cancer.
Patel R; Brzezinska EA; Repiscak P; Ahmad I; Mui E; Gao M; Blomme A; Harle V; Tan EH; Malviya G; Mrowinska A; Loveridge CJ; Rushworth LK; Edwards J; Ntala C; Nixon C; Hedley A; Mackay G; Tardito S; Sansom OJ; Leung HY
Cancer Res; 2020 Feb; 80(3):576-590. PubMed ID: 31719098
[TBL] [Abstract][Full Text] [Related]
6. The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens.
Schweizer L; Rizzo CA; Spires TE; Platero JS; Wu Q; Lin TA; Gottardis MM; Attar RM
BMC Cell Biol; 2008 Jan; 9():4. PubMed ID: 18218096
[TBL] [Abstract][Full Text] [Related]
7. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
8. Targeting Crosstalk between Nrf-2, NF-κB and Androgen Receptor Signaling in Prostate Cancer.
Khurana N; Sikka SC
Cancers (Basel); 2018 Sep; 10(10):. PubMed ID: 30257470
[TBL] [Abstract][Full Text] [Related]
9. Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer.
Terry S; Yang X; Chen MW; Vacherot F; Buttyan R
J Cell Biochem; 2006 Oct; 99(2):402-10. PubMed ID: 16741972
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Wnt/β-catenin pathway overcomes therapeutic resistance to abiraterone in castration-resistant prostate cancer.
Atawia IM; Kushwaha PP; Verma S; Lin S; Shankar E; Abdel-Gawad O; Gupta S
Mol Carcinog; 2023 Sep; 62(9):1312-1324. PubMed ID: 37232341
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor: what we know and what we expect in castration-resistant prostate cancer.
Cai Z; Chen W; Zhang J; Li H
Int Urol Nephrol; 2018 Oct; 50(10):1753-1764. PubMed ID: 30128923
[TBL] [Abstract][Full Text] [Related]
12. A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland.
Pakula H; Xiang D; Li Z
Cancers (Basel); 2017 Jan; 9(2):. PubMed ID: 28134791
[TBL] [Abstract][Full Text] [Related]
13. SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells.
Wang H; McKnight NC; Zhang T; Lu ML; Balk SP; Yuan X
Cancer Res; 2007 Jan; 67(2):528-36. PubMed ID: 17234760
[TBL] [Abstract][Full Text] [Related]
14. Glycogen synthase kinase-3 inhibitors suppress the AR-V7-mediated transcription and selectively inhibit cell growth in AR-V7-positive prostate cancer cells.
Nakata D; Koyama R; Nakayama K; Kitazawa S; Watanabe T; Hara T
Prostate; 2017 Jun; 77(9):955-961. PubMed ID: 28397338
[TBL] [Abstract][Full Text] [Related]
15. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer.
Savoy RM; Chen L; Siddiqui S; Melgoza FU; Durbin-Johnson B; Drake C; Jathal MK; Bose S; Steele TM; Mooso BA; D'Abronzo LS; Fry WH; Carraway KL; Mudryj M; Ghosh PM
Endocr Relat Cancer; 2015 Jun; 22(3):369-86. PubMed ID: 25759396
[TBL] [Abstract][Full Text] [Related]
16. Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer.
Han W; Gao S; Barrett D; Ahmed M; Han D; Macoska JA; He HH; Cai C
Oncogene; 2018 Feb; 37(6):710-721. PubMed ID: 29059155
[TBL] [Abstract][Full Text] [Related]
17. Wnt/Beta-Catenin Signaling and Prostate Cancer Therapy Resistance.
Yeh Y; Guo Q; Connelly Z; Cheng S; Yang S; Prieto-Dominguez N; Yu X
Adv Exp Med Biol; 2019; 1210():351-378. PubMed ID: 31900917
[TBL] [Abstract][Full Text] [Related]
18. Cotargeting Polo-Like Kinase 1 and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer.
Li J; Karki A; Hodges KB; Ahmad N; Zoubeidi A; Strebhardt K; Ratliff TL; Konieczny SF; Liu X
Mol Cell Biol; 2015 Dec; 35(24):4185-98. PubMed ID: 26438599
[TBL] [Abstract][Full Text] [Related]
19. Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells.
Lee E; Ha S; Logan SK
PLoS One; 2015; 10(10):e0141589. PubMed ID: 26509262
[TBL] [Abstract][Full Text] [Related]
20. Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer.
Perner S; Cronauer MV; Schrader AJ; Klocker H; Culig Z; Baniahmad A
Oncotarget; 2015 Nov; 6(34):35542-55. PubMed ID: 26325261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
